US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PhaseRx

0.2806

0.0000

Volume:- -

Turnover:- -

Market Cap:3.28M

PE:-0.23

High:0.2806

Open:0.2806

Low:0.2806

Close:0.2806

52wk High:1.95

52wk Low:0.2228

Shares:11.69M

Float Shares:3.70M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2400

ROE:--

ROA:--

PB:-10.90

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

PhaseRx

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.phaserx.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. Its initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology platform and is applicable to various inherited liver diseases. Its product pipeline includes PRX-OTC for Ornithine Transarbamylase deficiency; PRX-ASL for Argininosuccinate Lyase deficiency; and PRX-ASS1 for Argininosuccinatesynthetase 1 deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PZRX/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PZRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PZRX\",,,,,undefined,":{"symbol":"PZRX","market":"US","secType":"STK","nameCN":"PhaseRx","latestPrice":0.2806,"timestamp":1517605200000,"preClose":0.2806,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":3700000,"shares":11690000,"eps":-1.24,"marketStatus":"Closed","change":0,"latestTime":"02-02 16:00:00 EST","open":0.2806,"high":0.2806,"low":0.2806,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.24,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781078400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1463544000000,"exchange":"NASDAQ","adjPreClose":0.2806,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PZRX\",,,,,undefined,":{"symbol":"PZRX","floatShares":3700000,"roa":"--","roe":"--","lyrEps":0,"shares":11690000,"dividePrice":0,"high":0.2806,"amplitude":0,"preClose":0.2806,"low":0.2806,"week52Low":0.2228,"pbRate":"-10.90","week52High":1.95,"institutionHeld":0,"latestPrice":0.2806,"eps":-1.24,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.24,"open":0.2806,"prevYearClose":0.2806},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PZRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-09","symbol":"PZRX","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.23},{"market":"US","date":"2017-08-10","symbol":"PZRX","fiscalQuarterEnding":"2017/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1502337600000,"reportTimeType":"","actualEps":-0.3},{"market":"US","date":"2017-05-12","symbol":"PZRX","fiscalQuarterEnding":"2017/03","expectedEps":-0.06,"name":null,"time":"","type":"earning","dateTimestamp":1494561600000,"reportTimeType":"","actualEps":-0.35},{"market":"US","date":"2017-03-27","symbol":"PZRX","fiscalQuarterEnding":"2016/12","expectedEps":-0.22,"name":null,"time":"","type":"earning","dateTimestamp":1490587200000,"reportTimeType":"","actualEps":-0.3},{"market":"US","date":"2016-11-07","symbol":"PZRX","fiscalQuarterEnding":"2016/09","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1478494800000,"reportTimeType":"","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PZRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PZRX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.phaserx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. Its initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology platform and is applicable to various inherited liver diseases. Its product pipeline includes PRX-OTC for Ornithine Transarbamylase deficiency; PRX-ASL for Argininosuccinate Lyase deficiency; and PRX-ASS1 for Argininosuccinatesynthetase 1 deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.","exchange":"NASDAQ","name":"PhaseRx","nameEN":"PhaseRx"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PZRX\",market:\"US\",,,undefined,":null}}